ABX464-103
60 evidence topics · 7 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Primary objective in the protocol: dose selection
Selected secondary objectives in the protocol
Rationale for the study in the protocol: phase 2a results
Location and study date
Registered locations
Centres, countries, and enrollment period in the published report
“In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Aug 13, 2019, and April 16, 2021, 254 patients were randomly allocated to ABX464 100 mg (n=64), ABX464 50 mg (n=63), ABX464 25 mg (n=63), or placebo (n=64).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trial registration printed in the published abstract
Study design
Randomised, double-blind, placebo-controlled, four-group design
“In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Enrolled patients were randomly assigned (1:1:1:1) via an interactive voice and web response system to receive once daily oral ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, or matched placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Randomisation was stratified according to study site (US vs non-US) and to whether the patient had previous exposure to second-line treatment with biologics or JAK inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double blind, placebo controlled, parallel groups” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Enrollment (actual) | “355” |
Treatment groups and duration in the ClinicalTrials.gov record
Limits on previous advanced therapy exposure, central endoscopy reading, and e-diaries
Endoscopy schedule and exit for disease progression
Duration of participation and roll-over to the open-label extension
Dose limiting toxicity rule and Data Safety Monitoring Board
Eligibility criteria
Key eligibility criteria in the published report
“Eligible patients were aged 18-75 years, with a diagnosis of moderate-to-severe, active ulcerative colitis and a modified Mayo Score (MMS) of 5 points or higher, and a documented non-response or intolerance to previous treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria in the ClinicalTrials.gov record: disease activity and previous treatment
Inclusion criteria in the ClinicalTrials.gov record: background therapy and washout
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and capsule regimens in the ClinicalTrials.gov record
Formulation and administration in the protocol
Allowed concomitant medications in the protocol
Prohibited medications in the protocol, including CYP1A2 substrates
Study outcomes
Rationale for using change in modified mayo score as the primary endpoint
Registered primary outcome measure and the modified Mayo score
Modified Mayo score compared with the total Mayo score in the protocol
Secondary endpoint definitions in the protocol: clinical remission, clinical response, endoscopic improvement, and mucosal healing
Central reading of endoscopy in the registered secondary outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size assumptions in the protocol
Participants consented, randomized, treated, and analyzed in the posted results
Exclusions from the full analysis set in the published report
Description of analysis sets
Full analysis set and safety population in the published report
“The primary efficacy analysis was done in the full analysis set (FAS), defined as all randomly assigned patients who received at least one dose of study treatment and had baseline data for at least one efficacy variable, and was analysed according to the principles of intention-to-treat.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Safety analyses included patients who had been randomly assigned and who received at least one dose of study treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets in the statistical analysis plan
Primary analysis model and fixed testing sequence in the protocol
Results
Participant disposition
Discontinuations and exclusions in the posted results
Baseline characteristics
Baseline characteristics in the posted results
| Characteristic | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo | Total |
|---|---|---|---|---|---|
| Participants | “64” | “63” | “61” | “64” | “252” |
| Age, years, mean (SD) | “42.2(12.34)” | “40.2(13.94)” | “41.5(14.16)” | “41.1(14.43)” | “41.2(13.67)” |
| Female | “23” | “36” | “21” | “24” | “104” |
| Male | “41” | “27” | “40” | “40” | “148” |
| Baseline MMS 5 to 6 | “17” | “16” | “17” | “21” | “71” |
| Baseline MMS 7 to 9 | “47” | “47” | “44” | “42” | “180” |
Race and ethnicity not collected
Disease severity and refractoriness of the induction population
“Of the 252 patients treated in the induction trial, baseline disease activity was severe (MMS of 7–9) in 71.4% of patients, and more than 45% of patients were refractory to 2 or more advanced targeted therapies at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Induction results reported in the maintenance study publication
“More than 45% had failed at least 2 prior advanced targeted therapies (biologics or JAK inhibitors). Obefazimod (25, 50, or 100 mg) significantly reduced the modified Mayo score (MMS) at week 8, meeting the primary endpoint. Improvements were seen in both naïve and bio/JAK refractory patients in key secondary outcomes, including clinical remission, response, endoscopic, and histologic–endoscopic mucosal improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: change from baseline in modified Mayo score at week 8
“In the FAS at week 8, the least squares mean (LSM) change from baseline in MMS was -2·9 (95% CI -3·4 to -2·5) for the ABX464 100 mg group, -3·2 (-3·7 to -2·7) for the ABX464 50 mg group, -3·1 (-3·6 to -2·6) for the ABX464 25 mg group, and -1·9 (-2·4 to -1·5) for placebo group; the magnitude of the difference in MMS from baseline was significantly greater in all three ABX464 groups compared with placebo (p=0·0039 for ABX464 100 mg vs placebo, p=0·0003 for ABX464 50 mg vs placebo, and p=0·0010 for ABX464 25 mg vs placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary outcome in the posted results: least squares mean change in MMS at week 8
| Group | Least squares mean | 95% confidence interval |
|---|---|---|
| ABX464 100 mg | “-2.9” | “(-3.4 to -2.5)” |
| ABX464 50 mg | “-3.2” | “(-3.7 to -2.7)” |
| ABX464 25 mg | “-3.1” | “(-3.6 to -2.6)” |
| Matching placebo | “-1.9” | “(-2.4 to -1.5)” |
Secondary outcomes at week 8 in the posted results: number of participants
| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
|---|---|---|---|---|
| Clinical remission per MMS (64, 63, 61, 64) | “16” | “11” | “16” | “8” |
| Clinical response (64, 63, 61, 64) | “32” | “37” | “38” | “22” |
| Endoscopic improvement (54, 53, 58, 59) | “24” | “21” | “20” | “8” |
| Endoscopic remission (54, 53, 58, 59) | “2” | “5” | “4” | “5” |
| Mucosal healing (64, 63, 61, 64) | “0” | “1” | “0” | “2” |
Secondary outcomes at week 16 in the posted results: number of participants
| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
|---|---|---|---|---|
| Clinical remission per MMS (31, 30, 37, 46) | “7” | “6” | “9” | “6” |
| Clinical response (31, 30, 37, 46) | “19” | “20” | “25” | “20” |
| Endoscopic improvement (32, 31, 38, 46) | “11” | “12” | “11” | “9” |
| Endoscopic remission (32, 31, 38, 46) | “1” | “1” | “2” | “3” |
Analysis population for the week 16 outcomes
Health-related quality of life and patient-reported outcomes
IBDQ planned as a secondary endpoint in the protocol
Stool frequency and rectal bleeding recorded in an electronic diary
Safety results
Headache and serious adverse events in the published report
“The most frequently reported adverse event was headache, which was reported for 27 (42%) of 64 patients in the ABX464 100 mg group, 19 (30%) of 63 in the 50 mg group, 13 (21%) of 62 in the 25 mg group, and five (8%) of 64 in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Severe (grade 3) headache was reported for three (5%) patients in the ABX464 group 100 mg group, two (3%) in the ABX464 50 mg group, one (2%) in the ABX464 25 mg group, and none in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The only serious adverse event reported for two or more patients in any group was ulcerative colitis (one in each of the ABX464 100 mg and 50 mg groups, and three [5%] in the placebo group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in the posted results: participants affected / at risk (%)
| Event | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
|---|---|---|---|---|
| All-cause mortality | “0/64 (0.00%)” | “0/63 (0.00%)” | “0/62 (0.00%)” | “0/64 (0.00%)” |
| Serious adverse events, total | “4/64 (6.25%)” | “4/63 (6.35%)” | “1/62 (1.61%)” | “4/64 (6.25%)” |
| Other adverse events, total | “45/64 (70.31%)” | “38/63 (60.32%)” | “33/62 (53.23%)” | “30/64 (46.88%)” |
| Headache | “27/64 (42.19%)” | “19/63 (30.16%)” | “13/62 (20.97%)” | “5/64 (7.81%)” |
| Nausea | “9/64 (14.06%)” | “4/63 (6.35%)” | “5/62 (8.06%)” | “4/64 (6.25%)” |
| Vomiting | “5/64 (7.81%)” | “2/63 (3.17%)” | “1/62 (1.61%)” | “1/64 (1.56%)” |
| Abdominal pain upper | “4/64 (6.25%)” | “3/63 (4.76%)” | “3/62 (4.84%)” | “0/64 (0.00%)” |
Adverse event collection period in the posted results
Study limitations
Summary
ABX464-103 was a phase 2b, randomized, double-blind, placebo-controlled dose-ranging induction trial with 4 parallel groups; 254 participants were randomized and 252 were included in the full analysis set. The primary endpoint was the change from baseline in modified Mayo score at week 8, and the protocol also defined clinical remission, clinical response, and endoscopic improvement as outcomes. The posted results report the primary outcome for 58, 54, 59, and 60 participants in the 100 mg, 50 mg, 25 mg, and placebo groups, against full analysis set sizes of 64, 63, 61, and 64. The protocol scheduled week 16 endoscopy only for participants without endoscopic improvement at week 8, and the week 16 outcomes were analyzed in participants “with data available for baseline and the respective visit”. The protocol limited participants with previous exposure to biologics or JAK inhibitors to 60%, those with previous vedolizumab to 20%, and those with previous JAK inhibitors to 10%. Of 252 participants, 2 were enrolled in the United States, and race and ethnicity were not collected. The protocol planned IBDQ assessment at Week 8 and Week 16, and no IBDQ results were located in the PubMed abstract or the posted results. Headache was reported in 27 of 64, 19 of 63, 13 of 62, and 5 of 64 participants in the 100 mg, 50 mg, 25 mg, and placebo groups. The PubMed abstract gives NCT04023396, the record of the open-label maintenance study, as the trial registration.